Terapevt Arkh
-
Multicenter Study Observational Study
[Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients' treatment].
To study the effect of levilimab or baricitinib in combination with standard therapy (ST) on the incidence of severe viral pneumonia associated with a new coronavirus infection COVID-19. ⋯ The addition of levilimab or baricitinib to the therapy regimen for coronavirus infection during the outpatient phase has demonstrated a preemptive anti-inflammatory effect and reduced the probability of lung tissue damage progression.